
About the Age-Related Macular Degeneration Session
Age-Related Macular Degeneration (AMD) stands as a prevalent cause of vision decline in individuals aged 50 and above. This condition specifically targets the macula, a crucial part of the retina essential for sharp, central vision. AMD manifests in two primary forms: dry AMD, characterized by a gradual deterioration of light-sensitive cells, and wet AMD, distinguished by abnormal blood vessel growth leading to swift vision impairment.
Various factors contribute to its development, including age, genetics, smoking, and dietary habits. Symptoms typically involve central vision distortion, color perception difficulties, and the appearance of wavy lines. While a cure remains elusive, treatments like anti-VEGF injections for wet AMD and lifestyle adjustments can help manage its progression. Consistent eye examinations play a pivotal role in early detection and effective management, highlighting the significance of proactive eye health practices as individuals age.
Topics Covered in Age-Related Macular Degeneration
Dry AMD & Geographic Atrophy
Neovascular AMD
Anti-VEGF Injections
Drusen & Early AMD
Genetic & Lifestyle Risk
AREDS Supplements
Featured Speakers — Age-Related Macular Degeneration 2027


Recent Research Presented at Age-Related Macular Degeneration Sessions
Stereotactic radiotherapy for wet age-related macular degeneration: year 4 results of a randomised, double-masked, sham-controlled trial
Aim: To investigate the long term, real-world safety and efficacy of Stereotactic Radiotherapy (SRT) for exudative Age-Related Macular Degeneration (AMD). Methods: This randomised, double-masked…
Correlation of choroidal thickness and c-reactive protein levels in patients with age-related macular degeneration
Age-Related Macular Degeneration (AMD) is a major cause of irreversible vision loss in the elderly population. Its pathogenesis is multifactorial, with inflammation and vascular changes playing…
Low Level Photo Bio Modulation LL PBM in geographic atrophy: A pivotal randomized single blind study follow up 12 months
Introduction: PhotoBioModulation (PBM) has emerged in recent years as a potential therapeutic approach to counteract the progression of dry Age Related Macular Degeneration (d AMD). Its primary…
Submacular haemorrhage due to wet age-related macular degeneration: What to do?
Aim: To consider the presentation, management options, and randomised controlled trials investigating submacular haemorrhage (SMH) secondary to neovascular age-related macular degeneration (AMD)…
Results of a photobiomodulation treatment in patients with macular degeneration age-related (ADM) with a new low-fluence, multifrequency wearable device: Positive medium-term effects (6 months) of visual function
Introduction: In our previous study, we demonstrated the efficacy and short-term safety of low-fluence photobiomodulation (LF-PBM) for atrophic macular degeneration (AMD) using a newly developed…
Automated system for analysis of oct retina images development and testing
Neovascular age-related macular degeneration (n-AMD) is a form of AMD that is responsible for most cases of severe vision loss. Anti-VEGF therapy, which is the gold standard for the treatment of this…
Related Scientific Sessions at IOC 2027
Why Attend the Age-Related Macular Degeneration Conference 2027
Earn CPD Credit
Sessions are CPD-accredited by The CPD Group (UK) — one CPD credit for every hour of attendance.
Present Your Research
Oral and poster slots for original Age-Related Macular Degeneration work, reviewed by the scientific committee.
Network Globally
Meet ophthalmologists, vision scientists, and eye-care clinicians from around the world across three days.
Publish & Get Indexed
Accepted abstracts are compiled into the conference proceedings and indexed in Scopus and Web of Science.
Learn from Keynotes
Plenary lectures from leading voices shaping Age-Related Macular Degeneration research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join IOC 2027 for the Age-Related Macular Degeneration track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Age-Related Macular Degeneration Conference 2027 — FAQs
What is the Age-Related Macular Degeneration track at IOC 2027?
The Age-Related Macular Degeneration track is a dedicated stream within IOC 2027 covering the latest research, clinical innovation, and best practice in Age-Related Macular Degeneration. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Age-Related Macular Degeneration sessions?
Ophthalmologists, optometrists, vision scientists, educators, doctoral students, and trainees with an interest in Age-Related Macular Degeneration are all welcome — whether presenting or attending.
Can I present my research in the Age-Related Macular Degeneration track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Age-Related Macular Degeneration sessions?
Yes. IOC 2027 is a hybrid conference — attend the Age-Related Macular Degeneration track in person in Singapore or join live online, with on-demand access afterward.
Join the IOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
